Alzheimer’s is one of the world’s most expensive diseases, costing around $1 trillion per year globally, research estimates. As cases are forecast to triple by 2050, this figure is only going to increase. To make matters worse, new research suggests that the per-person cost of treatment is also growing.
Cerba Healthcare, France’s largest laboratory group by revenue, has acquired Yourlab, a medium-sized clinical pathology company based in the west of France.
Both Korian and Orpea’s share prices increased more than 10% after the release of investigative TV show Cash Investigation’s hidden camera episode revealing scenes inside a Korian nursing home. Meanwhile Orpea’s expansion into Russia has been halted after last week’s invasion of Ukraine and French public investment bank Bpifrance pulled out.
French elderly care giant Korian is having to walk a fine line between reporting a return to strong revenue and earnings growth in 2021 whilst simultaneously affirming its commitment to always putting the welfare of its residents and quality of care first. The approach it has adopted is to herald the launch of a new strategy: to become a ‘mission-led’ company! Meanwhile Orpea has postponed its annual results until at last as April 30.
Circle Health, the UK’s largest for-profit hospital group, has partnered with global medtech company GE Healthcare, in a 10-year deal that will see GE provide equipment, software and consulting services. GE Healthcare’s general manager of EMEA solutions, John Deverill, explains why such deals are becoming increasingly common.
Giant health care conglomerate Fresenius SE has publicly floated the possibility of bringing minority equity shareholders in at the level of divisions such as Vamed or Helios in its 2021 results announcement. It has even suggested it could sell its controlling stake in dialysis arm Fresenius Medical Care. But at least one investment bank is publicly stating this doesn't go far enough.
Finnish outsourcing specialist Pihlajalinna posted some reasonable looking financials, on the face of it, for the full year to January 31, 2021 on Friday last week - so why have its shares dropped around 11% at the time of writing?
Multiple sources have told HBI that fast-growing German and Swiss ophthalmology group Sanoptis might be looking at a Q2 sale, but HBI understands that is not entirely correct. HBI speaks to Sanoptis CEO Volker Wendel to set the record straight.
Pan-Nordic care group Attendo achieved modest revenue growth in 2021, whilst its occupancy level almost recovered to pre-pandemic levels. But it made a slight loss after taxes and its share price at SEK30.17 is down 70% from the 2017 peak.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
